Dr Mark Murakami

Assistant Professor, Medicine, Harvard Medical School
Investigator, Hematologic Neoplasia,
Dana-Farber Cancer Institute

Host: Dr Katherine Antel

Dr Mark Murakami is a hematologist and medical oncologist who specializes in the treatment of patients with leukemia and lymphoma. As an Assistant Professor of Medicine at Harvard Medical School, his research laboratory at the Dana-Farber Cancer Institute seeks to detect, biologically define, and target minimal residual disease (MRD) and therapy resistance in B-cell malignancies within the context of preclinical patient-derived models and early phase clinical trials. He leads clinical molecular diagnostics initiatives for lymphoma at Dana-Farber, including the development of tissue based and cell-free DNA sequencing platforms for clinical and investigational use. Complementing these efforts, he contributes to the creation of institutional clinical and genomic data repositories to facilitate high-quality retrospective research that can generate hypotheses for prospective investigation.